- Joined
- Nov 15, 2020
- Messages
- 3
- Reaction score
- 1
Will this be better than Lotemax?
Excerpt:
Eysuvis utilizes Kala’s Ampplify mucus-penetrating particle (MPP) drug delivery technology to enhance penetration of loteprednol etabonate into target tissue on the ocular surface. Loteprednol etabonate targets the immune responses that drive acute dry eye disease flares. Prior to Eysuvis, there were no FDA-approved ocular corticosteroids for the treatment of dry eye disease.
eyewire.news
Excerpt:
Eysuvis utilizes Kala’s Ampplify mucus-penetrating particle (MPP) drug delivery technology to enhance penetration of loteprednol etabonate into target tissue on the ocular surface. Loteprednol etabonate targets the immune responses that drive acute dry eye disease flares. Prior to Eysuvis, there were no FDA-approved ocular corticosteroids for the treatment of dry eye disease.

Kala Pharmaceuticals Receives FDA Approval of Dry Eye Disease Treatment Eysuvis - Eyewire+
The FDA on Tuesday approved Kala Pharmaceuticals’ Eysuvis (loteprednol etabonate ophthalmic suspension 0.25%), making it the first ocular corti
